Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM – Get Rating) COO Michael Cruse bought 3,212 shares of the stock in a transaction on Wednesday, August 31st. The shares were acquired at an average cost of $3.21 per share, with a total value of $10,310.52. Following the purchase, the chief operating officer now owns 6,197 shares of the company’s stock, valued at approximately $19,892.37. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Michael Cruse also recently made the following trade(s):
- On Monday, August 29th, Michael Cruse bought 83 shares of Reneo Pharmaceuticals stock. The shares were acquired at an average cost of $3.24 per share, with a total value of $268.92.
Reneo Pharmaceuticals Price Performance
Reneo Pharmaceuticals stock opened at $3.29 on Friday. The company has a market capitalization of $80.54 million, a P/E ratio of -1.62 and a beta of 1.41. The business has a 50 day moving average of $2.97 and a 200-day moving average of $2.99. Reneo Pharmaceuticals, Inc. has a 1 year low of $1.92 and a 1 year high of $10.72.
Analyst Upgrades and Downgrades
Several research analysts have recently issued reports on RPHM shares. SVB Leerink reaffirmed an “outperform” rating on shares of Reneo Pharmaceuticals in a research note on Tuesday, May 10th. Piper Sandler upped their price objective on Reneo Pharmaceuticals from $18.00 to $25.00 and gave the company an “outperform” rating in a research note on Tuesday, July 26th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $28.20.
Institutional Trading of Reneo Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd acquired a new stake in Reneo Pharmaceuticals during the 4th quarter valued at approximately $115,000. Commonwealth Equity Services LLC acquired a new stake in Reneo Pharmaceuticals during the 1st quarter valued at approximately $65,000. Renaissance Technologies LLC acquired a new stake in Reneo Pharmaceuticals during the 2nd quarter valued at approximately $61,000. Bank of America Corp DE boosted its holdings in shares of Reneo Pharmaceuticals by 24.0% during the 1st quarter. Bank of America Corp DE now owns 40,878 shares of the company’s stock worth $121,000 after buying an additional 7,914 shares in the last quarter. Finally, UBS Group AG boosted its holdings in shares of Reneo Pharmaceuticals by 5,012.5% during the 2nd quarter. UBS Group AG now owns 54,550 shares of the company’s stock worth $145,000 after buying an additional 53,483 shares in the last quarter. Institutional investors and hedge funds own 75.45% of the company’s stock.
About Reneo Pharmaceuticals
Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V.
- Get a free copy of the StockNews.com research report on Reneo Pharmaceuticals (RPHM)
- Could Snap Stock Rebound As Management Restructures?
- MarketBeat: Week in Review 8/29 – 9/2
- Hormel Looks Cheap At These Levels
- Lululemon Set To Soar Into September
- Could Nike Stock be Oversold, but Still Overvalued?
Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.